Recombinant interferon α-2b in the treatment of genital herpes: clinical and laboratory rationale and efficacy evaluation

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2021-01-01 DOI:10.20953/1729-9225-2021-3-58-66

O. Gizinger

{"title":"Recombinant interferon α-2b in the treatment of genital herpes: clinical and laboratory rationale and efficacy evaluation","authors":"O. Gizinger","doi":"10.20953/1729-9225-2021-3-58-66","DOIUrl":null,"url":null,"abstract":"According to the World Health Organization, a significant part of the population is susceptible to diseases caused by herpes viruses, among which genital herpes occupies a leading position in the incidence and severity of clinical manifestations. A promising strategy for the treatment of herpesvirus infections caused by herpes simplex virus (HSV) types 1 and 2 is the use of recombinant interferon-α preparations. Objective. To conduct a comparative analysis of the efficacy of using recombinant interferon α-2b with an active substance content of 1.000.000 IU and 3.000.000 IU in the treatment of genital herpesvirus infection. Patients and methods. A retrospective study of 100 patients with recurrent genital herpes 5.5 ± 1.25 per year at the age from 20 to 52 was carried out. The diagnosis was made based on complaints, clinical examination results and laboratory parameters. The presence of herpes virus antigen in the sample material, clinical status, clinical and biochemical parameters of peripheral blood, and the activity of antioxidant enzymes were assessed. Results. The maximum efficacy of therapy for genital herpesvirus infection was registered in patients who received complex treatment with valacyclovir and recombinant interferon α-2b with antioxidants at a dosage of 3.000.000 IU. Key words: antioxidant status, genital herpes, immunity, interferon α-2b","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2021-3-58-66","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

According to the World Health Organization, a significant part of the population is susceptible to diseases caused by herpes viruses, among which genital herpes occupies a leading position in the incidence and severity of clinical manifestations. A promising strategy for the treatment of herpesvirus infections caused by herpes simplex virus (HSV) types 1 and 2 is the use of recombinant interferon-α preparations. Objective. To conduct a comparative analysis of the efficacy of using recombinant interferon α-2b with an active substance content of 1.000.000 IU and 3.000.000 IU in the treatment of genital herpesvirus infection. Patients and methods. A retrospective study of 100 patients with recurrent genital herpes 5.5 ± 1.25 per year at the age from 20 to 52 was carried out. The diagnosis was made based on complaints, clinical examination results and laboratory parameters. The presence of herpes virus antigen in the sample material, clinical status, clinical and biochemical parameters of peripheral blood, and the activity of antioxidant enzymes were assessed. Results. The maximum efficacy of therapy for genital herpesvirus infection was registered in patients who received complex treatment with valacyclovir and recombinant interferon α-2b with antioxidants at a dosage of 3.000.000 IU. Key words: antioxidant status, genital herpes, immunity, interferon α-2b

查看原文本刊更多论文

重组干扰素α-2b治疗生殖器疱疹:临床和实验室原理及疗效评价

根据世界卫生组织的报告，相当一部分人口易患疱疹病毒引起的疾病，其中生殖器疱疹在发病率和临床表现的严重程度上占据领先地位。重组干扰素-α制剂是治疗由单纯疱疹病毒(HSV) 1型和2型引起的疱疹病毒感染的一种有前景的策略。目标。比较分析活性物质含量分别为100万IU和300万IU的重组干扰素α-2b治疗生殖器疱疹病毒感染的疗效。患者和方法。对100例年龄在20 ~ 52岁，每年(5.5±1.25)例复发性生殖器疱疹患者进行回顾性研究。根据主诉、临床检查结果和实验室参数作出诊断。检测样品材料中疱疹病毒抗原的存在、临床状态、外周血临床生化指标及抗氧化酶活性。结果。在接受valacyclovir和重组干扰素α-2b联合抗氧化剂剂量为300万IU的患者中，生殖器疱疹病毒感染的治疗效果最大。关键词:抗氧化状态，生殖器疱疹，免疫，干扰素α-2b

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.